According to recent reports, Eli Lilly’s promising Alzheimer’s treatment, donanemab, may be blocked for use by Britain’s National Health Service (NHS). The
Eli Lilly’s recent announcement of a raised revenue forecast due to strong demand for its weight-loss treatment Zepbound and related diabetes drug
Eli Lilly, a leading pharmaceutical company, is under renewed scrutiny as U.S. inspectors unveil fresh manufacturing problems at its Branchburg, New Jersey